Stockholders approve 2.7M share increase under 2018 Equity Plan, re-elect all directors at annual meeting

Travere Therapeutics, Inc.

All ten director nominees elected; John A. Orwin received 43.7M for vs 14.9M withheld.
2018 Equity Plan amended to add 2.7M authorized shares; vote 36.4M for, 22.1M against.
Advisory say-on-pay passed with 55.8M for, 2.9M against, 42k abstain.
Ernst & Young ratified as FY2024 auditor with 60.5M for, 2.2M against, 52k abstain.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Travere Therapeutics, Inc. shareholders approved Approval of the Company’s 2018 Equity Incentive Plan, as amended at the 2024-05-08 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2024-05-08

Exact text from the filing

The Company’s stockholders approved the 2018 Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by 2,700,000.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Travere Therapeutics, Inc. shareholders approved Election of Directors at the 2024-05-08 meeting.

Proposal: director election
Outcome: passed
Meeting: 2024-05-08

Exact text from the filing

The Company’s stockholders elected the ten persons listed below to serve until the Company’s 2025 Annual Meeting of Stockholders.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Travere Therapeutics, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2024-05-08 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2024-05-08

Exact text from the filing

The Company’s stockholders ratified the selection by the Audit Committee of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Travere Therapeutics, Inc. shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers at the 2024-05-08 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2024-05-08

Exact text from the filing

The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers.

View on SEC.gov

637 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Travere Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001438533-24-000022

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.